Ella Daly
Scientist/medical affairs researcher at Janssen Scientific Affairs, LLC
Data updated
Papers
Trials
Research Footprint
Ella Daly appears in 6 tracked papers (2016–2022), most studied alongside Ketamine, Esketamine and Placebo, across Depressive Disorders, Treatment-Resistant Depression (TRD) and Anxiety Disorders.
Most-cited paper: A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression (526 citations).
Frequent co-authors: Jaskaran Singh, Ibrahim Turkoz and William Drevets.
Background & Research
Ella J. Daly appears to be a psychiatric drug-development researcher whose publications are concentrated in ketamine/esketamine studies for treatment-resistant depression. PubMed records show her affiliated with Janssen Scientific Affairs and Janssen Research & Development, and earlier work lists her at the University of Texas Southwestern Medical Center.
Key Impact
She has coauthored multiple clinical trials and post hoc analyses on ketamine and esketamine for treatment-resistant depression, helping shape the evidence base for rapid-acting antidepressant therapies.
Collaboration Network
12 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Ella Daly is associated with.
Janssen Scientific Affairs, LLC
Janssen Research & Development
pharmaJanssen Research & Development is the pharmaceutical research and development arm of Johnson & Johnson (J&J). Operating under J&J's Innovative Medicine division, Janssen has sponsored clinical trials into ketamine-derived compounds, including esketamine (Spravato), the first FDA-approved psychedelic-adjacent treatment for treatment-resistant depression.
View stakeholder →